Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three-Way drug showdown targets Fish-Borne liver fluke

NCT ID NCT07074444

Cure Sponsor: First Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 01, 2026 · Last updated Oct 02, 2026 · Updated 1 time

Summary

Researchers compare three antiparasitic drugs, albendazole, tribendimidine, and praziquantel, for treating clonorchiasis, a liver fluke infection people get from eating raw or undercooked freshwater fish. The trial enrolls 318 adults in Guangxi, China, who have confirmed Clonorchis sinensis infection. Participants are randomly assigned to one of the three drugs and provide stool samples before and after treatment to check whether the parasite eggs are cleared. They also report side effects and attend follow-up visits with blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albendazole, tribendimidine, and praziquantel
What this could lead to
If one drug clears the infection better with fewer side effects, doctors could have a clearer first choice for treating liver fluke infections.
What could go wrong
This is a mid-stage trial, and the drugs may work about equally well or cause unexpected side effects. Results in adults in one region may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 318 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥18 years. 2. Confirmed diagnosis of Clonorchis sinensis infection based on the latest Expert Consensus on Diagnosis and Treatment of Food-Borne Parasitic Diseases (2023): detection of eggs or adult worms in stool or bile drainage fluid. 3. Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Known hypersensitivity or allergy to albendazole, praziquantel, or tribendimidine. 2. Electrocardiogram (ECG)-confirmed supraventricular tachycardia or atrial fibrillation. 3. Clinically or radiologically diagnosed neurocysticercosis (brain or spinal cord) or ocular cysticercosis (eye or orbit). 4. Presence of gallbladder stones or biliary tract obstruction as confirmed by abdominal ultrasound. 5. Individuals with severe hepatic, renal, or cardiac dysfunction, or with active peptic ulcer disease. 6. Pregnant or breastfeeding individuals, or those of reproductive potential (male or female) who are unwilling to use effective contraception during the study period and for 3 months following the last dose of study medication. 7. Anticipated loss to follow-up due to relocation, withdrawal of consent, or other factors affecting adherence to the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clonorchiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonorchiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clonorchiasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • People's Hospital of Guangxi Zhuang Autonomous Region

    RECRUITING

    Nanning, Guangxi, 530021, China

  • The First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, 530021, China